French food and beverage maker Danone said on Friday it was recalling specific baby formula batches in targeted markets, as a toxin contamination scare that started with Nestle products continued to s... ...

Core Insights - Abbott Laboratories has projected that its first-quarter profit will fall short of Wall Street expectations due to the need to offer discounts on nutrition products to attract price-sensitive customers, resulting in a significant drop in share prices [1][4] Financial Performance - The company anticipates adjusted earnings per share for the first quarter to be between $1.12 and $1.18, compared to the Wall Street average estimate of $1.19 [2] - In the fourth quarter, Abbott reported sales of $11.5 billion, which was below the average analyst estimate of $11.8 billion. Nutrition sales were particularly disappointing at $1.9 billion, falling short of the $2.19 billion estimate [3] Business Strategy - Abbott is shifting its nutrition business focus towards sustainable volume growth, which may impact performance in the first half of the year but is expected to position the business for long-term success. The company plans to launch eight new nutrition products in 2026 [5] Market Dynamics - The adult nutrition unit, which includes protein-focused drinks for individuals on weight-loss medications, has seen growth in recent quarters. However, the company faces challenges due to lawsuits alleging that its baby formula may cause necrotizing enterocolitis (NEC) in premature infants [6] Segment Performance - Abbott's largest business unit, medical devices, generated $5.67 billion in sales during the fourth quarter, aligning with estimates. This division includes products that assist diabetics in monitoring blood sugar levels [7] - The diagnostics unit has experienced a decline in demand following the pandemic, particularly for Covid-19 tests. Abbott has agreed to acquire Exact Sciences Corp. for approximately $21 billion, which is expected to enhance its diagnostics business by providing access to cancer screening tests [8]

Nestle has recalled a batch of baby formula after routine quality checks detected some issues, Ethiopia's Food and Drug Authority said in a statement on Thursday. ...

Target, Walmart, and Whole Foods will be added as defendants in lawsuits against baby formula maker ByHeart for selling a product potentially contaminated with spores that cause infant botulism. https://t.co/AwIdx8cRBo ...

Core Viewpoint - The U.S. Food and Drug Administration (FDA) has issued warning letters to four major retailers for selling baby formula associated with a bacterial illness outbreak in infants, despite prior advisories [1] Group 1: Regulatory Actions - The FDA's warning letters highlight ongoing concerns regarding the safety of baby formula products in the market [1] - The retailers involved have been identified as continuing to sell products linked to the outbreak, raising questions about compliance with health regulations [1] Group 2: Health Implications - The bacterial illness outbreak has significant implications for infant health, necessitating immediate action from both retailers and regulatory bodies [1] - The situation underscores the importance of stringent safety measures in the baby formula industry to protect vulnerable populations [1]

An outbreak of infant botulism linked to ByHeart’s baby formula is much wider than initially thought, potentially dating back two years, US health agencies said Wednesday https://t.co/yX1IEpcolg ...

Before the botulism outbreak, ByHeart sold its baby formula using wellness buzz words. https://t.co/26RBtkKTvD ...

Fed up with brands that use corn syrup and skim milk, this mother developed her own ‘clean’ baby formula | TechCrunch https://t.co/nIQBTbWnW9 ...